76 related articles for article (PubMed ID: 38397112)
1. Development of Orthotopic Patient-Derived Xenograft Models of Pediatric Intracranial Tumors.
Upton DH; Ziegler DS; Tsoli M
Methods Mol Biol; 2024; 2806():75-90. PubMed ID: 38676797
[TBL] [Abstract][Full Text] [Related]
2. Establishment of an orthotopic glioblastoma mouse model for preclinical studies.
Iturrioz-Rodríguez N; Piccardi F; Bertorelli R; Ciofani G
Methods Cell Biol; 2024; 185():49-65. PubMed ID: 38556451
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Orthotopic Xenograft Models for High-Grade Pediatric Brain Cancers.
Buck J; Hii H; Endersby R
Methods Mol Biol; 2024; 2806():41-53. PubMed ID: 38676795
[TBL] [Abstract][Full Text] [Related]
4. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
5. Murine models to study human NK cells in human solid tumors.
Parodi M; Astigiano S; Carrega P; Pietra G; Vitale C; Damele L; Grottoli M; Guevara Lopez ML; Ferracini R; Bertolini G; Roato I; Vitale M; Orecchia P
Front Immunol; 2023; 14():1209237. PubMed ID: 37388731
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis.
Morimoto T; Nakazawa T; Matsuda R; Maeoka R; Nishimura F; Nakamura M; Yamada S; Park YS; Tsujimura T; Nakagawa I
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397112
[TBL] [Abstract][Full Text] [Related]
7. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
8. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
9. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Front Immunol; 2018; 9():824. PubMed ID: 29740437
[TBL] [Abstract][Full Text] [Related]
10. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.
Maeoka R; Nakazawa T; Matsuda R; Morimoto T; Shida Y; Yamada S; Nishimura F; Nakamura M; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762486
[TBL] [Abstract][Full Text] [Related]
13. N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor.
Lou C; Wu K; Shi J; Dai Z; Xu Q
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096526
[TBL] [Abstract][Full Text] [Related]
14. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Yamada S; Nakagawa I; Park YS; Nakase H; Tsujimura T
Regen Ther; 2022 Dec; 21():185-191. PubMed ID: 35919498
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
